CD9 and cancer: Indeed, CD9 is often downregulated in advanced stages of cancer, and its absence is a sign of poor prognosis in patients with lung, breast, colon, skin, ovary, uterus, stomach, oral cavity, thyroid, prostate, and hematopoietic malignancies (3, 75).